Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Vincent Meininger , Angela Genge (1) , Leonard van den Berg (2) , Wim Robberecht (3) , Albert Ludolph (4) , Adriano Chiò (5) , Seung Kim , P Nigel Leigh (6) , Matt Kiernan (7) , Jeremy Shefner (8) , Claude Desnuelle (9) , Karen Morrison (10, 11) , Susanne Petri (12) , Diane Boswell (13) , Jane Temple (13) , Rajat Mohindra (13) , Matt Davies (13) , Jonathan Bullman (13) , Paul Rees (13) , Arseniy Lavrov (13) , William Camu (14) , Jerzy Daniluk , Anne Dekker , Alain Destée , Matthew Devine , Stephen Dewall , Johannes Dorst , Giuseppe Fuda , Harutoshi Fujimura , Andreas Funke , Torsten Grehl , Julian Grosskreutz , Usha Gungabissoon , Rob Henderson , Peggy Ho , William Huynh , Saiju Jacob , Raul Juntas-Morales (14) , Byung-Jo Kim , Xenia Kobeleva , Sonja Koerner , Stephen Kolb , Katja Kollewe , Lawrence Korngut , Géraldine Lautrette (15) , Amy Lee , Anthony Lynch , Rami Massie , Genevieve Matte , Darryl Menezes , Stefano Milleri , Linda Nichols , Kazutoshi Nishiyama , Mieko Ogino , Chris Parkinson , Pierre-François Pradat , Tino Prell , Jeffrey Price , Eleanor Ramsey , Thomas Ringer , Kristiana Salmon , Christen Shoesmith , Marie Helene Soriani , Marloes Stam , Erik Steinberg , Rob Stubbs , Herman Sullivan , Philip van Damme (3) , Michael van Es , Anne Visser , Mary Lou Watson , Andrea Sylvia Winkler , Lorne Zinman , Margie Zoing

1 Montreal Neurological Institute and Hospital
2 University Medical Center [Utrecht]
3 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
4 Universität Ulm - Ulm University [Ulm, Allemagne]
5 UNITO - Università degli studi di Torino = University of Turin
6 BSMS - Brighton and Sussex Medical School
7 The University of Sydney
8 Barrow Neurological Institute
9 COMUE UCA - COMUE Université Côte d'Azur (2015-2019)
10 University of Birmingham [Birmingham]
11 University of Southampton
12 MHH - Medizinische Hochschule Hannover = Hannover Medical School
13 GlaxoSmithKline
14 INM - Institut des Neurosciences de Montpellier
15 Service de Neurologie [CHU Limoges]

Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive effect in the SOD1G93A mouse model of ALS, and a humanised form of this antibody (ozanezumab) was well tolerated in a first-in-human trial. Therefore, we aimed to assess the safety and efficacy of ozanezumab in patients with ALS.

Domaines: Médecine humaine et pathologie; Neurosciences [q-bio.NC]

Vincent Meininger, Angela Genge, Leonard van den Berg, Wim Robberecht, Albert Ludolph, et al.. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology, 2017, 16 (3), pp.208 - 216. ⟨10.1016/S1474-4422(16)30399-4⟩. ⟨hal-01785450⟩